About us

Professor Boris C. Pasche is Chairman of the Board and CEO of TheraBionic Inc. and Geschäftsführer of TheraBionic GmbH. He is coinventor of the TheraBionic technology, cofounder of TheraBionic Inc., formerly TheraBionic LLC, and TheraBionic GmbH, companies focused on the commercialization of TheraBionic’s novel technology for the treatment of cancer. Since 2014, Dr. Pasche has served as attending physician at Wake Forest Medical Center, Director of Wake Forest Baptist Comprehensive Cancer Center, and Chairman, Department of Cancer Biology at Wake Forest University. He is the recipient of the Charles L. Spurr Endowed Chair in Cancer Research.

Professor Pasche received his M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden and a M.D. degree from the University of Lausanne, Switzerland. Following a postdoctoral fellowship in Dr. Joseph Loscalzo’s lab at the Brigham and Women’s Hospital, Harvard Medical School, Dr. Pasche did a residency in Internal Medicine at the New York Hospital, Cornell Medical Center. He then undertook his clinical training in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center where he did a second postdoctoral fellowship in the lab of Dr. Joan Massagué, Howard Hughes Medical Institute and Sloan-Kettering Institute for Cancer Research. In 2000 he was recruited to Northwestern University, where he spent eight years and established the Cancer Genetics Program, before being recruited by the University of Alabama at Birmingham as the Director of the Division of Hematology/Oncology, and Martha Ann and David L. May Chair in Cancer Research. He also served as the Associate Director for Translational Research and then Deputy Director of the University of Alabama Comprehensive Cancer Center.

Professor Pasche has co-authored more than 120 articles and numerous books and book chapters. He has served on multiple study sections for NCI, ACS, AACR, DOD and the Komen Foundation. He is a recipient of the Ohio State University Human Cancer Genetics Program Commemorative Medal and is an elected member of the American Society for Clinical Investigation (ASCI) and the American Clinical and Climatological Association (ACCA).

Regina Müller-Vollmer is the Chief Operating Officer of TheraBionic GmbH, manufacturer of the TheraBionic P1, since its establishment in Ettlingen. She is quality management representative and responsible for the development and monitoring of the QM system in accordance with EN ISO 13485:2016.

As environmental officer in a pharmaceutical company, she successfully introduced the environmental management system at all production sites and continued to develop it further. It was awarded an environmental prize by the state of Baden-Württemberg for commercial companies. In her function as department head for project management she was responsible for the efficient annual planning and resource coordination of all projects in the company as well as the development of her employees. Her work in the recent years has consisted of the performance of internal and external audits, the development and training of employees, the monitoring of legal conformity as well as public relations and association work.

As part of her self-employment as an environmental management consultant, she established one of the first environmental management systems in Germany.

She received a diploma in biology following her studies at the Westfälische Wilhelms University in Münster.